Industries > Pharma > Asthma and COPD Therapies: World Market 2013-2023
Asthma and COPD Therapies: World Market 2013-2023
New study reveals sales potential of this large, expanding market
See what the future holds for asthma and COPD therapies. Visiongain's report gives you drug revenue predictions to 2023. You find data, trends, opportunities and commercial prospects.
That new study lets you assess forecasted sales at overall world market, submarket, product, company and national level. You see why the asthma and COPD market will grow, as we predict.
In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, R&D and commercial developments. You receive 114 tables, 210 charts and four research interviews, including two with executives from GSK.
The following sections highlight what you discover in the report.
Prospects for submarkets and products
In addition to analyses of the overall world market, you see revenue forecasting of three world-level submarkets to 2023:
• Bronchodilators (Mono-therapy)
• Anti-inflammatory drugs
• Combination drugs
Also, you see how 19 leading drugs – including Seretide/Advair, Singulair, Spiriva, Symbicort and Pulmicort – can perform to 2023.
Prospects for leading countries shown to 2023
Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for asthma and COPD therapies.
You discover revenue forecasts to 2023 for eleven national markets:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5 nations)
• India
• China
• Brazil
• Russia.
This decade, revenues from India and China will be among the fastest growing worldwide. In particular, product launches from 2013 onwards will benefit regional and national markets.
Research and development activities
What's happening in the R&D drug pipeline? You see developmental trends there:
• Monoclonal antibodies
• Ultra-Long Acting Beta-2 Agonists
• Muscarinic Antagonist Beta-2 Agonists
• Anti-leukotriene agents
• LAMA/LABA Combinations
• Developments in delivery systems
• Developments in telehealth
Discover how technological progress changes the sector. Our investigation explains, bringing together many issues.
Prominent issues affecting the asthma and COPD market
Our study lets you assess industry trends and outlooks worldwide from 2013. As the work shows, many issues affect the industry and market:
• An increasingly mature asthma market
• Patient adherence
• Patient management techniques
• Reimbursement, regulations, patent expiries and generic competition
• An increasingly segregated patient population
You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.
Discussions of leading companies and prospects for market growth
What will happen next? The pharmaceutical industry will improve treatments for asthma and COPD and increase revenues there from 2013 to 2023. The R&D pipeline is strong. Our work shows you what technologies and organisations hold greatest potential. See profiles of seven leading companies, including these:
• GSK
• Boehringer Ingelheim
• Merck
• AstraZeneca
In general, a company profile gives you the following information:
• Discussion of a company's activities and outlook
• Assessment of its developments – mergers and acquisitions (M&A), new products, and collaborations.
• Forecasting of asthma and COPD drug revenues to 2023
Overall world revenue for that market area will reach $34.51bn in 2013, our report forecasts. Ageing populations, educational initiatives, improved drug delivery and new formulations will increase sales of asthma and COPD therapies.
Nine ways Asthma and COPD Therapies: World Market 2013-2023 benefits you
In particular, then, our study gives you the following knowledge on asthma and COPD therapies:
• Forecasted revenues to 2023 for the overall world market and submarkets
• Potential revenues of 19 leading products to 2023
• Potential revenues of 6 promising drugs that are currently in development
• Market forecasting to 2023 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India, China, Brazil and Russia.
• Assessment of companies – discussions of activities and outlooks
• Review of R&D pipelines by treatment area – progress and trends
• Opinions on the sector, including our research interviews with leaders in industry
• Investigation of competition and opportunities influencing sales
• Discussion of what stimulates and restrains the industry and market.
That work gives independent analyses from our primary and secondary research. You receive information found only in our report.
With our study, you find business intelligence to help you understand the future of that industry and market.
Ordering now lets you discover prospects for asthma and COPD therapies
Visiongain's study is for everybody needing commercial analyses of asthma and COPD therapies. You find data, trends and predictions there. Please order that report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
To view free sample pages of this report please click here
1. Executive Summary
1.1 Key Findings
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. Introduction to Asthma & COPD Therapies
2.1 Introduction
2.2 Overview of Respiratory Disorders
2.3 What is Asthma?
2.3.1 Symptoms of Asthma
2.3.2 Causes and Triggers of Asthma
2.3.3 Trends in Asthma Prevalence
2.3.4 Guidelines for Asthma Treatment
2.3.5 Economic Burden of Asthma
2.3.6 Current Treatments for Asthma
2.3.7 Delivery Method - Types of Inhaler
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 What are the Signs and Symptoms of COPD?
2.4.2 Management of COPD
2.4.3 Guidelines for COPD Management
2.4.4 Trends in COPD Prevalence
2.4.5 Economic Burden of COPD
2.5 Major Drug Classes in Treating Respiratory Diseases
2.5.1 Bronchodilators
2.5.1.1 Beta-2 (Adrenoreceptor) Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids (ICS)
2.5.2.2 Leukotriene Inhibitors
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.5.4 Antihistamines
3. The Asthma and COPD Therapies Market 2013-2023
3.1 The Global Respiratory Market
3.1.1 Growing Market for Respiratory Treatments
3.1.2 The World Respiratory Market: Breakdown by Disorders
3.2 The World Asthma & COPD Therapies Market
3.2.1 Growing Market for Asthma & COPD Drug Treatments
3.2.2 The World Asthma and COPD Therapies Market: Market Shares Forecast by Therapy Area 2013-2023
3.2.3 Asthma and COPD Therapies: World Sales Forecast by Therapy Area 2013-2017
3.2.4 Asthma and COPD Therapies: World Sales Forecast by Therapy Area 2018-2023
3.2.5 The World Asthma Therapies Market
3.2.5.1 The World Asthma Therapies Market: Sales Forecast 2013-2017
3.2.5.2 The World Asthma Therapies Market: Sales Forecast 2018-2023
3.2.6 The World COPD Therapies Market
3.2.6.1 The World COPD Therapies Market: Sales Forecast 2013-2017
3.2.6.2 The World COPD Therapies Market: Sales Forecast 2018-2023
3.2.7 World Asthma and COPD Therapies Market: Market Shares by Drug Class, 2012
3.2.8 World Asthma and COPD Therapies Market: Market Share Forecasts by Drug Class 2013-2023
3.2.9 Asthma and COPD Therapies: World Sales Forecast by Drug Classes 2013-2017
3.2.10 Asthma and COPD Therapies: World Sales Forecast by Drug Class 2018-2023
3.2.11 Global Asthma and COPD Therapies Market: Drivers and Restraints, 2013-2023
4. Bronchodilators Mono-therapy Drugs: World Market, 2013-2023
4.1 Introduction
4.2 The World Bronchodilators Mono-Therapy Market: Market Shares by Type
4.3 The World Bronchodilators Mono-Therapy Market: Market Shares Forecast by Type 2013-2023
4.4 The World Bronchodilators Mono-Therapy Market: Sales Forecast by Type 2013-2017
4.5 The World Bronchodilators Mono-Therapy Market: Sales Forecast by Type 2018-2023
4.6 The World Short-Acting Beta-2 Agonists (SABA) Market
4.6.1 The World Short-Acting Beta-2 Agonist (SABA) Market: Market Shares by Leading Drugs, 2012
4.6.2 The World Short-Acting Beta-2 Agonist (SABA) Market: Market Share Forecast by Leading Drugs, 2013-2023
4.6.3 The World Short-Acting Beta 2 Agonist (SABA) Market: Sales Forecast by Leading Drugs 2013-2017
4.6.4 The World Short-Acting Beta-2 Agonist (SABA) Market: Sales Forecast by Leading Drugs 2018-2023
4.6.5 Ventolin
4.6.5.1 Ventolin: World Sales, 2012
4.6.5.2 Ventolin: World Sales Forecast 2013-2017
4.6.5.3 Ventolin: World Sales Forecast 2018-2023
4.6.6 ProAir
4.6.6.1 ProAir: World Sales, 2012
4.6.6.2 ProAir: World Sales Forecast 2013-2017
4.6.6.3 ProAir: World Sales Forecast 2018-2023
4.6.7 Xopenex
4.6.7.1 Xopenex: World Sales, 2012
4.6.7.2 Xopenex: World Sales Forecast 2013-2023
4.6.7.3 Xopenex: World Sales Forecast 2018-2023
4.6.8 Proventil
4.6.8.1 Proventil: World Sales, 2012
4.6.8.2 Proventil: World Sales Forecast 2013-2017
4.6.8.3 Proventil: World Sales Forecast 2018-2023
4.7 The World Long-Acting Beta-2 Agonists (LABA) Mono-therapy Market 2013-2023
4.7.1 Overview
4.7.2 The World Long-Acting Beta-2 Agonists (LABA) Mono-therapy Market: Market Shares by Leading Drugs, 2012
4.7.3 The World Long-Acting Beta-2 Agonists (LABA) Mono-therapy Market: Market Shares Forecast by Drugs 2013-2023
4.7.4 The World Long-Acting Beta 2 Agonists (LABA) Mono-therapy Market: Sales Forecast by Leading Drugs 2013-2017
4.7.5 The World Long-Acting Beta 2 Agonists (LABA) Mono-therapy Market: Sales Forecast by Leading Drugs 2018-2023
4.7.6 Serevent
4.7.6.1 Serevent: World Sales, 2012
4.7.6.2 Serevent: World Sales Forecast 2013-2017
4.7.6.3 Serevent: World Sales Forecast 2018-2023
4.7.7 Foradil/Foradile
4.7.7.1 Foradil: World Sales, 2012
4.7.7.2 Foradil: World Sales Forecast 2013-2017
4.7.7.3 Foradil: World Sales Forecast 2018-2023
4.7.8 Onbrez Breezhaler
4.7.8.1 Onbrez Breezhaler: World Sales, 2012
4.7.8.2 Onbrez Breezhaler: World Sales Forecast 2013-2017
4.7.8.3 Onbrez Breezhaler: World Sales Forecast 2018-2023
4.8 The World Anticholinergic Mono-Therapy Drug Market 2013-2023
4.8.1 Introduction
4.8.2 The World Anticholinergic Mono-Therapy Drug Market: Market Shares by Leading Drugs, 2012
4.8.3 The World Anticholinergic Mono-Therapy Drug Market: Market Share Forecast by Leading Drugs 2013-2023
4.8.4 The World Anticholinergic Mono-Therapy Drug Market: Sales Forecast by Leading Drugs 2013-2017
4.8.5 The World Anticholinergic Mono-Therapy Drug Market: Sales Forecast by Leading Drugs 2018-2023
4.8.6 Spiriva
4.8.6.1 Spiriva Continues to Grow Strongly
4.8.6.2 Safety Concerns and the UPLIFT Trial
4.8.6.3 Results of the POET Study
4.8.6.4 Competition and Other Restraints
4.8.6.5 Spiriva: World Sales Forecast 2013-2017
4.8.6.6 Spiriva: World Sales Forecast 2018-2023
4.8.7 Atrovent
4.8.7.1Atrovent: World Sales Forecast 2013-2017
4.8.7.2 Atrovent: World Sales Forecast 2018-2023
5. The Anti-Inflammatory Drugs Market 2013-2023
5.1 Introduction
5.2 The World Asthma and COPD Market: Anti-Inflammatory Drugs Market Share by Type, 2012
5.3 The World Asthma and COPD Market: Anti-Inflammatory Drugs Market Share Forecast by Types 2013-2023
5.4 The World Asthma and COPD Market: Anti-Inflammatory Drugs Sales Forecast by Type 2013-2017
5.5 The World Asthma and COPD Market: Anti-Inflammatory Drugs Sales Forecast by Type 2018-2023
5.6 The World Asthma and COPD Market: Corticosteroids
5.6.1 Introduction
5.6.2 The World Asthma and COPD Market: Corticosteroids Market Shares by Leading Drugs, 2012
5.6.3 The World Asthma and COPD Market: Corticosteroids Market Share Forecast by Leading Drugs 2013-2023
5.6.4 The World Asthma and COPD Market: Corticosteroids Sales Forecast by Leading Drugs 2013-2017
5.6.5 The World Corticosteroid Market: Sales Forecast by Leading Drugs 2018-2023
5.6.6 Flixotide
5.6.6.1 Flixotide: World Sales
5.6.6.2 Flixotide: World Sales Forecast 2013-2017
5.6.6.3 Flixotide: World Sales Forecast 2018-2023
5.6.7 Pulmicort
5.6.7.1 Pulmicort: World Sales
5.6.7.2 Pulmicort: World Sales Forecast 2013-2017
5.6.7.3 Pulmicort: World Sales Forecast 2018-2023
5.6.8 Qvar
5.6.8.1 Qvar: World Sales
5.6.8.2 Qvar: World Sales Forecast 2013-2017
5.6.8.3 Qvar: World Sales Forecast 2018-2023
5.6.9 Asmanex
5.6.9.1 Asmanex: World Sales
5.6.9.2 Asmanex: World Sales Forecast 2013-2017
5.6.9.3 Asmanex: World Sales Forecast 2018-2023
5.7 The World Anti-Leukotrienes Market 2013-2023
5.7.1 Introduction
5.7.2 The World Anti-Leukotrienes Market: Market Shares by Leading Drugs, 2012
5.7.3 The World Anti-Leukotrienes Market: Market Share Forecast by Leading Drugs 2013-2023
5.7.4 The World Anti-Leukotrienes Market: Sales Forecast by Leading Drugs 2013-2017
5.7.5 The World Anti-Leukotrienes Market: Sales Forecast by Leading Drugs 2018-2023
5.7.6 Singulair
5.7.6.1 Patent Expired, Generics Approved
5.7.6.2 Singulair: World Sales, 2012
5.7.6.3 Singulair: World Sales Forecast 2013-2017
5.7.6.4 Singulair: World Sales Forecast 2018-2023
5.8 The World Asthma and COPD Market: Monoclonal Antibodies 2013-2023
5.8.1 Introduction
5.8.2 The World Asthma and COPD Market: Monoclonal Antibodies Market Share Forecast by Drugs, 2013-2023
5.8.3 The World Asthma and COPD Market: Monoclonal Antibodies Sales Forecast by Drugs 2013-2017
5.8.4 The World Asthma and COPD Market: Monoclonal Antibodies Sales Forecast by Drugs 2018-2023
5.8.5 Xolair
5.8.5.1 NICE Reimbursement Issues in the UK
5.8.5.2 Xolair: World Sales
5.8.5.3 Xolair: World Sales Forecast 2013-2017
5.8.5.4 Xolair: World Sales Forecast 2018-2023
6. The World Combination Drugs Market 2013-2023
6.1 Introduction
6.2 The World Combination Drugs Market: Market Shares by Leading Drugs, 2012
6.3 The World Combination Drugs Market: Market Shares Forecast by Leading Drugs 2013-2023
6.4 The World Combination Drugs Market: Sales Forecast by Leading Drugs 2013-2023
6.5 The World Combination Drugs Market: Sales Forecast by Leading Drugs 2018-2023
6.6 Seretide/Advair
6.6.1 Will Generic Advair Ever Reach the Market?
6.6.2 Breo/Relvar: Advair Part II?
6.6.3 Seretide/Advair: World Sales, 2012
6.6.4 Seretide/Advair: World Sales Forecast 2013-2017
6.6.5 Seretide/Advair: World Sales Forecast 2018-2023
6.7 Symbicort
6.7.1 Symbicort and the COPD Indication
6.7.2 Symbicort: The SMART Concept
6.7.3 Symbicort: World Sales, 2012
6.7.4 Symbicort: World Sales Forecast 2013-2017
6.7.5 Symbicort: World Sales Forecast 2018-2023
6.8 Combivent
6.8.1 Combivent: World Sales, 2012
6.8.2 Combivent: World Sales Forecast 2013-2017
6.8.3 Combivent: World Sales Forecast 2018-2023
6.9 Dulera
6.9.1 Dulera: World Sales, 2012
6.9.2 Dulera: World Sales Forecast 2013-2017
6.9.3 Dulera: World Sales Forecast 2018-2023
7. Leading National Markets 2013-2023
7.1 Introduction
7.2 The Asthma and COPD Market: Breakdown by Region
7.3 Global Asthma and COPD Market: Market Share Forecast by Region 2013-2023
7.4 Global Asthma and COPD Market: Revenue Forecast by National Markets 2013-2017
7.5 Global Asthma and COPD Market: Revenue Forecast by National Markets 2018-2023
7.6 The US Asthma & COPD Therapies Market, 2013-2023
7.7 The Japanese Market: Second-Largest National Market in 2012
7.8 Market Projections for the EU5 Group, 2013-2023
7.8.1 The EU5 Asthma and COPD Markets: Market Shares by Countries, 2012
7.8.2 The EU5 Asthma and COPD Market: Market Shares Forecast by Countries 2013-2023
7.8.3 The EU5 Markets: Revenue Forecast by Countries, 2013-2017
7.8.4 The EU5 Markets: Revenue Forecast by Countries, 2018-2023
7.9 BRIC Nations: The Rapid Growth Area for Pharma
7.9.1 BRIC Nations: Market Shares by Countries, 2012
7.9.2 The BRIC Asthma and COPD Market: Market Shares Forecast by Countries 2013-2023
7.9.3 The BRIC Nations: Sales Forecasts by Country 2013-2017
7.9.4 The BRIC Nations: Sales Forecast by Country 2018-2023
8. Leading Companies in the Asthma & COPD Therapies Market 2013-2023
8.1 Introduction
8.2 The Global Asthma and COPD Market: Market Shares by Leading Companies, 2012
8.3 Market Shares Forecast by Leading Companies 2013-2023
8.4 Global Asthma and COPD Market: Revenue Forecast by Leading Companies, 2013-2017
8.5 Global Asthma and COPD Market: Revenue Forecast by Leading Companies, 2018-2023
8.6 GSK
8.6.1 Introduction
8.6.2 Leading Asthma and COPD Products
8.6.3 GSK: Revenue Shares by Leading Products, 2012
8.6.4 GSK: Asthma and COPD Revenue Forecast by Drugs 2013-2017
8.6.5 GSK: Asthma and COPD Revenue Forecast by Drugs 2018-2023
8.7 Boehringer Ingelheim
8.7.1 Introduction
8.7.2 Leading Asthma and COPD products
8.7.3 Boehringer Ingelheim Asthma and COPD Segment: Revenue Shares by Leading Products, 2012
8.7.4 Boehringer Ingelheim: Asthma and COPD Revenue Forecast by Drugs 2013-2017
8.7.5 Boehringer Ingelheim: Asthma and COPD Revenue Forecast by Drugs, 2018-2023
8.8 Merck
8.8.1 Introduction
8.8.2 Leading Products
8.8.3 Merck: Asthma and COPD Revenues Share by Leading Products, 2012
8.8.4 Merck: Asthma and COPD Revenue Forecast by Drugs 2013-2017
8.8.5 Merck: Asthma and COPD Revenue Forecast by Drugs 2018-2023
8.9 AstraZeneca
8.9.1 Introduction
8.9.2 Leading Products
8.9.3 AstraZeneca: Asthma and COPD Revenue Shares by Leading Products, 2012
8.9.4 AstraZeneca: Asthma and COPD Revenue Forecast by Drugs, 2013-2017
8.9.5 AstraZeneca: Asthma and COPD Revenue Forecast by Drugs, 2018-2023
8.10 Novartis
8.10.1 Introduction
8.10.2 Leading Products
8.10.3 Novartis: Asthma and COPD Revenue Breakdown by Leading Products
8.10.4 Novartis: Asthma and COPD Sales Forecast by Drugs, 2013-2017
8.10.5 Novartis: Asthma and COPD Sales Forecast by Drugs, 2018-2023
8.11 Teva Pharmaceuticals
8.11.1 Introduction
8.11.2 Leading Products
8.11.3 Teva: Asthma and COPD Revenue Shares by Leading Products, 2012
8.11.4 Teva: Asthma and COPD Revenue Forecast by Drugs, 2013-2017
8.11.5 Teva: Asthma and COPD Revenue Forecast by Drugs, 2018-2023
9. R&D Pipeline Analysis and Future Prospects for the Asthma and COPD Market 2013-2023
9.1 Introduction
9.2 Asthma and COPD Pipelines
9.2.1 Breo Ellipta
9.2.2 Anoro
9.2.3 QVA149
9.2.4 Seebri Breezhaler
9.3 Recent and Potential Developments in Asthma and COPD
9.3.1 Ultra-Long Acting Beta-2 Agonists
9.3.1.2 Muscarinic Antagonist Beta-2 Agonist (MABA)
9.3.1.3 Anti-Leukotriene Agents
9.3.1.4 Monoclonal Antibodies
9.3.1.5 LAMA/LABA Combinations
9.3.2 Developments in Diagnostics
9.3.2.1 Diagnostic Imaging: Parametric Response Mapping for COPD
9.3.2.2 Biological Markers
9.3.3 Developments in Delivery Systems (Inhalers)
9.3.3.1 GSK: Ellipta
9.3.3.2 AstraZeneca: SMART Inhaler
9.3.3.3 Boehringer: Respimat SoftMist
9.3.4 Developments in Patient Management: Telehealth
9.3.4.1 Introduction
9.3.4.2 Telehealth for Asthma and COPD Patients
9.3.4.3 The Potential Impact of Telehealth on the Asthma and COPD Drug Market
9.3.5 Educational Projects and Agencies
9.3.5.1 Potential Impact on the Drugs Market
10. SWOT Analysis: Factors Influencing the Asthma and COPD Market
10.1 Introduction
10.2 Asthma & COPD Therapeutics: A Key Sector in Respiratory Diseases
10.3 Commercial Drivers of the Asthma Therapies Market
10.3.1 Expanding Patient Population
10.3.2 High Economic Cost of Respiratory Diseases
10.3.3 Changing Perception of COPD
10.3.4 Educating the Masses: Understanding the Severity of Respiratory Disease
10.3.5 Management Rather than Cure
10.3.6 Lifecycle Management Strategies to Counter Patent Expiry
10.3.7 Advanced Inhaler Technologies to Counter Generic Erosion
10.3.8 Brand Awareness
10.3.9 Diverse and Segregated Population
10.3.10 Rapidly Rising BRIC Countries
10.4 Principal Restraints for Respiratory Therapeutics
10.4.1 The Threat of Generics
10.4.2 Restrictions on Healthcare Budgets Favour the Use of Generics
10.4.3 Purchasers Hold Increased Bargaining Power in Asthma
10.4.4 Maturation of the Asthma Market
10.4.5 Ghost Population in COPD
11. Expert Opinion
11.1 Research Interview: Ms Monica Fletcher, OBE Chief Executive, Education for Health and Chair, European Lung Foundation (ELF)
11.1.1The Importance of Education
11.1.2 Educating Healthcare Professionals and Patients
11.1.3 Mixture of Detriments of Appropriate COPD Diagnosis and A Missed COPD Population
11.1.4 COPD: A Global Issue and A Changing Disease
11.1.5 Unmet Needs in Asthma and COPD
11.1.6 Educational Measures Undertaken by Education for Health and ELF
11.1.7 Views on Telehealth
11.1.8 Varying Impact of Education on Asthma and COPD
11.2 Research Interview: Dr Daphne Tsitoura, Senior Medical Director, Clinical Drug Development/Discovery Medicine - GlaxoSmithKline
11.2.1 Unmet Needs
11.2.2 The Asthma Market: Reaching Saturation?
11.2.3 Phenotypically-Tailored Therapies?
11.2.4 Difficulties with COPD Diagnosis
11.2.5 Importance of Inhalers in the Asthma and COPD market
11.2.6 Industry Emphasis on COPD?
11.2.7 Combinations for COPD
11.2.8 Views on Telehealth
11.2.9 Views on Personalised Medicine
11.2.10 On Novel Targets
11.2.11 Where Will the Asthma and COPD Market Be Ten Years from Now?
11.2.11.1 Diagnostics
11.2.11.2 Drugs
11.2.11.3 Education
11.3 Research Interview: Dr Barbara Yawn, MD, MSc, FAAFP; Director of Research, Olmsted Medical Center, and Adjunct Professor, Department of Family and Community Health, University of Minnesota, USA
11.3.1 Unmet Needs
11.3.2 The Impact of Inhalers in Asthma and COPD
11.3.3 On Developments in Drugs
11.3.4 Diverse Conditions and Segregated Population
11.3.5 On Personalised Medicine
11.3.6 Leukotriene Inhibitors
11.3.7 Anti-Inflammatory Drugs: More Research Required
11.3.8 LABA Mono-therapy Drugs: Fading Away?
11.3.9 LABA/LAMA Drugs
11.3.10 On Telehealth
11.3.11 Under-Diagnosis in COPD
11.3.12 Where Will The Asthma and COPD Market Be Ten Years from Now
11.3.12.1 Education
11.3.12.2 Drugs
11.3.12.3 Diagnostics
11.3.12.4 Patient Management
11.4 Research Interview: Mr Ahmed Wagih, Product Manager-Respiratory Franchise (Seretide, Flixotide and Ventolin) at GlaxoSmithKline
11.4.1 Rising Prevalence of COPD
11.4.2 Shifting Market Trend
11.4.3 The Guideline Complexities
11.4.4 Complicated and Diverse Market
11.4.5 Key Areas of Focus
11.4.6 Generic Competition
11.4.7 COPD Diagnostics
11.4.8 On LAMA/LABA Combinations
11.4.9 On Telehealth
11.4.10 On Personalised Medicine?
12. Conclusion
12.1 Introduction
12.2 Leading Drug Classes and Drugs in the Market
12.3 Leading National Markets
12.4 Leading Companies in the Market
12.5 Combination Drugs Such as Seretide/Advair Continue to Dominate
12.6 New LABA/LAMA Combinations Will Halt Spiriva's Growth
12.7 Segregated Market?
12.8 Addressing Unmet Needs Offers Potential for Revenue Growth
12.9 Market Moving Towards Personalised Medicine?
12.10 Concluding Remarks
List of Tables
Table 2.1 Common Respiratory Diseases
Table 2.2 Causes of Asthma
Table 2.3 Triggers of Asthma
Table 2.4 Major Drug Classes Used in the Treatment of Asthma and COPD
Table 3.1 The World Respiratory Market: Revenues ($bn) and Market Shares (%) by Therapy Area, 2012
Table 3.2 Asthma and COPD Therapies: World Sales Forecast by Therapy Area ($bn, AGR%, CAGR%), 2012-2017
Table 3.3 Asthma and COPD Therapies: World Sales Forecast by Therapy Area ($bn, AGR%, CAGR%), 2018-2023
Table 3.4 The World Asthma Therapies Market: Sales Forecast, ($bn, AGR%, CAGR%), 2012-2017
Table 3.5 The World Asthma Therapies Market: Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 3.6 The World COPD Therapies Market: Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 3.7 The World COPD Therapies Market: Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 3.8 World Asthma and COPD Therapies Market: Revenues ($bn) and Market Shares (%) by Drug Class, 2012
Table 3.9 Asthma and COPD Therapies: World Sales Forecast by Drug Class ($bn, AGR%, CAGR%), 2012-2017
Table 3.10 Asthma and COPD Therapies: World Sales Forecast by Drug Class ($bn, AGR%, CAGR%), 2018-2023
Table 3.11 Global Asthma and COPD Market Drivers and Restraints
Table 4.1 The World Bronchodilators Market: Revenues ($bn) and Market Shares (%) by Type, 2012
Table 4.2 The World Bronchodilators Mono-Therapy: Sales Forecast ($bn, AGR%, CAGR%) by Type, 2012-2017
Table 4.3 The World Bronchodilators Mono-Therapy: Sales Forecast ($bn, AGR%, CAGR%) by Type, 2018-2023
Table 4.4 The World Short-Acting Beta-2 Agonist (SABA) Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2012
Table 4.5 The World Short-Acting Beta-2 Agonist (SABA) Market: Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2012-2017
Table 4.6 The World Short-Acting Beta 2 Agonist (SABA) Market: Sales Forecast ($bn, AGR%, CAGR %) by Leading Drugs, 2018-2023
Table 4.7 Ventolin: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 4.8 Ventolin: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 4.9 ProAir: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 4.10 ProAir: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 4.11 Xopenex: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 4.12 Xopenex: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 4.13 Proventil: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 4.14 Proventil: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 4.15 The World Long-Acting Beta-2 Agonists (LABA) Mono-Therapy Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2012
Table 4.16 World Long-Acting Beta 2 Agonist Mono-Therapy Market: Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2012-2017
Table 4.17 World Long-Acting Beta-2 Agonist Mono-Therapy Market: Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2018-2023
Table 4.18 Serevent: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 4.19 Serevent: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 4.20 Foradil: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 4.21 Foradil: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 4.22 Onbrez Breezhaler: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 4.23 Onbrez Breezhaler: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 4.24 The World Anticholinergic Mono-Therapy Drug Market: Revenues ($bn) and Market Shares (%) by Leading Drugs 2012
Table 4.25 The World Anticholinergic Mono-Therapy Drug Market: Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2012-2017
Table 4.26 The World Anticholinergic Mono-Therapy Drug Market: Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2018-2023
Table 4.27 Spiriva: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 4.28 Spiriva: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 4.29 Atrovent: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 4.30 Atrovent: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 5.1 The World Asthma and COPD Market: Anti-Inflammatory Drugs Revenues ($bn) and Market Shares (%) by Type, 2012
Table 5.2 The World Asthma and COPD Market: Anti-Inflammatory Drugs Sales Forecast ($bn, AGR%, CAGR%) by Types, 2012-2017
Table 5.3 The World Asthma and COPD Market: Anti-Inflammatory Drugs Sales Forecast ($bn, AGR%, CAGR%) by Type, 2018-2023
Table 5.4 The World Asthma and COPD Market: Corticosteroids Revenues ($bn) and Market Shares (%) by Leading Drugs, 2012
Table 5.5 The World Asthma and COPD Market: Corticosteroids Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2012-2017
Table 5.6 The World Asthma and COPD Market: Corticosteroids Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2018-2023
Table 5.7 Flixotide: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 5.8 Flixotide: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 5.9 Pulmicort: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 5.10 Pulmicort: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 5.11 Qvar: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 5.12 Qvar: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 5.13 Asmanex: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 5.14 Asmanex: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 5.15 The World Anti-leukotrienes Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2012
Table 5.16 The World Anti-Leukotrienes Market: Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2012-2017
Table 5.17 The World Anti-Leukotrienes Market: Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2018-2023
Table 5.18 Singulair: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 5.19 Singulair: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 5.20 The World Asthma and COPD Market: Monoclonal Antibodies Sales Forecast ($bn, AGR%, CAGR%) by Drugs, 2012-2017
Table 5.21 The World Asthma and COPD Market: Monoclonal Antibodies Sales Forecast ($bn, AGR%, CAGR%) by Drugs, 2018-2023
Table 5.22 Xolair: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 5.23 Xolair: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 6.1 The World Combination Drugs Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2012
Table 6.2 The World Combination Drug Market: Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2012-2017
Table 6.3 The World Combination Drug Market: Sales Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2018-2023
Table 6.4 Seretide/Advair Market: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 6.5 Seretide/Advair: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 6.6 Symbicort: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 6.7 Symbicort: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 6.8 Combivent: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 6.9 Combivent: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 6.10 Dulera: World Sales Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 6.11 Dulera: World Sales Forecast ($bn, AGR%, CAGR%), 2018-2023
Table 7.1 The Global Asthma and COPD Market: Revenues ($bn) and Market Shares (%) by Region, 2012
Table 7.2 Global Asthma and COPD Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2012-2017
Table 7.3 Global Asthma and COPD Market: Revenues Forecast ($bn, AGR%, CAGR%) by Region, 2018-2023
Table 7.4 The US Asthma and COPD Market: Sales Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 7.5 The Japanese Asthma and COPD Market: Sales Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 7.6 The EU5 Asthma and COPD Markets: Revenues ($bn) and Market Shares (%) by Country, 2012
Table 7.7 The EU5 Asthma and COPD Markets: Revenue Forecast ($bn, AGR%, CAGR%) by Country, 2012-2017
Table 7.8 The EU5 Asthma and COPD Markets: Revenue Forecast ($bn, AGR%, CAGR%) by Country, 2018-2023
Table 7.9 The BRIC Nations: Revenues ($bn) and Market Shares (%) by Country, 2012
Table 7.10 The BRIC Nations: Sales Forecast ($bn, AGR%, CAGR%) by Country, 2012-2017
Table 7.11 The BRIC Nations: Sales Forecast ($bn, AGR%, CAGR%) by Country, 2018-2023
Table 8.1 Global Asthma and COPD Market: Revenues ($bn) and Market Shares (%) by Leading Companies, 2012
Table 8.2 Global Asthma and COPD Market: Revenue Forecast ($bn, AGR%, CAGR%) by Leading Companies, 2012-2017
Table 8.3 Global Asthma and COPD Market: Revenue Forecast ($bn, AGR%, CAGR%) by Company, 2018-2023
Table 8.4 GSK: Revenues ($bn) and Revenue Shares (%) by Leading Products, 2012
Table 8.5 GSK: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2012-2017
Table 8.6 GSK: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2018-2023
Table 8.7 Boehringer: Asthma and COPD Revenues ($bn) and Revenue Shares (%) by Leading Products, 2012
Table 8.8 Boehringer: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2012-2017
Table 8.9 Boehringer: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2018-2023
Table 8.10 Merck: Asthma and COPD Revenues ($bn) and Revenue Shares (%) by Leading Products, 2012
Table 8.11 Merck: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2012-2017
Table 8.12 Merck: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2018-2023
Table 8.13 AstraZeneca: Asthma and COPD Revenues ($bn) and Revenue Shares (%) by Leading Products, 2012
Table 8.14 AstraZeneca: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2012-2017
Table 8.15 AstraZeneca: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2018-2023
Table 8.16 Novartis: Asthma and COPD Revenues ($bn) and Revenue Shares (%) by Leading Products, 2012
Table 8.17 Novartis Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2012-2017
Table 8.18 Novartis: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2018-2023
Table 8.19 Teva: Asthma and COPD Revenues ($bn) and Revenue Shares (%) by Leading Products, 2012
Table 8.20 Teva: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2012-2017
Table 8.21 Teva: Asthma and COPD Revenue Forecast ($bn, AGR%, CAGR%) by Drugs, 2018-2023
Table 9.1 Asthma & COPD Drug Pipeline by Company, 2013
Table 9.1 (continued..) Asthma and COPD Drug Pipeline by Company, 2013
Table 10.1 SWOT Analysis of the World Asthma and COPD Market: Strengths and Weaknesses
Table 10.2 SWOT Analysis of The World Asthma and COPD Market: Opportunities and Threats
List of Figures
Figure 2.1 GINA guidelines for Asthma Treatment
Figure 2.2 GOLD guidelines for COPD Treatment
Figure 3.1 The World Respiratory Market: Market Shares (%) by Therapy Area, 2012
Figure 3.2 The World Respiratory Market: Revenues ($bn) by Therapy Area, 2012
Figure 3.3 The World Asthma and COPD Therapies Market: Market Shares (%) by Therapy Area, 2012
Figure 3.4 The World Asthma and COPD Therapies Market: Revenues ($bn) by Therapy Area, 2012
Figure 3.5 The World Asthma and COPD Therapies Market: Market Shares (%) by Therapy Area, 2017
Figure 3.6 The World Asthma and COPD Therapies Market: Revenues ($bn) by Therapy Area, 2017
Figure 3.7 The World Asthma and COPD Therapies Market: Market Shares (%) by Therapy Area, 2023
Figure 3.8 The World Asthma and COPD Therapies Market: Revenues ($bn) by Therapy Area, 2023
Figure 3.9 Asthma and COPD Therapies: World Sales Forecast by Therapy Area ($bn), 2012-2017
Figure 3.10 Asthma and COPD Therapies: World Sales Forecast by Therapy Area ($bn), 2018-2023
Figure 3.11 The World Asthma Therapies Market: Sales Forecast ($bn), 2012-2017
Figure 3.12 The World Asthma Therapies Market: Sales Forecast ($bn), 2018-2023
Figure 3.13 The World COPD Therapies Market: Sales Forecast ($bn), 2012-2017
Figure 3.14 The World COPD Therapies Market: Sales Forecast ($bn), 2018-2023
Figure 3.15 World Asthma and COPD Therapies Market: Market Shares (%) by Drug Class, 2012
Figure 3.16 World Asthma and COPD Therapies Market: Revenues ($bn) by Drug Class, 2012
Figure 3.17 The World Asthma and COPD Therapies Market: Market Shares (%) by Drug Class, 2017
Figure 3.18 The World Asthma and COPD Therapies Market: Revenues ($bn) by Drug Class, 2017
Figure 3.19 The World Asthma and COPD Therapies Market: Market Shares (%) by Drug Class, 2023
Figure 3.20 The World Asthma and COPD Therapies Market: Revenues ($bn) by Drug Class, 2023
Figure 3.21 Asthma and COPD Therapies: World Sales Forecast by Drug Class ($bn), 2012-2017
Figure 3.22 Asthma and COPD Therapies: World Sales Forecast by Drug Class ($bn), 2018-2023
Figure 4.1 The World Bronchodilators Market: Market Shares (%) by Type, 2012
Figure 4.2 The World Bronchodilators Market: Revenues ($bn) by Type, 2012
Figure 4.3 The World Bronchodilators Mono-Therapy Market: Market Shares (%) by Type, 2017
Figure 4.4 The World Bronchodilators Mono-Therapy Market: Revenues ($bn) by Type, 2017
Figure 4.5 The World Bronchodilators Mono-Therapy Market: Market Shares (%) by Type, 2023
Figure 4.6 The World Bronchodilators Mono-Therapy Market: Revenues ($bn) by Type, 2017
Figure 4.7 The World Bronchodilators Mono-Therapy: Sales Forecast ($bn) by Type, 2012-2017
Figure 4.8 The World Bronchodilators Mono-Therapy: Sales Forecast ($bn) by Type, 2018-2023
Figure 4.9 The World Short-Acting Beta-2 Agonist (SABA) Market: Market Shares (%) by Leading Drugs, 2012
Figure 4.10 The World Short-Acting Beta-2 Agonist (SABA) Market: Revenues ($bn) by Leading Drugs, 2012
Figure 4.11 The World SABA Market: Market Shares (%) by Leading Drugs, 2017
Figure 4.12 The World SABA Market: Revenues ($bn) by Leading Drugs, 2017
Figure 4.13 The World SABA Market: Revenue Share (%) by Leading Drugs, 2023
Figure 4.14 The World SABA Market: Revenues ($bn) by Leading Drugs, 2023
Figure 4.15 The World Short-Acting Beta-2 Agonist (SABA) Market: Sales Forecast ($bn) by Leading Drugs, 2012-2017
Figure 4.16 The World Short-Acting Beta-2 Agonist Market: Sales Forecast ($bn) by Leading Drugs, 2018-2023
Figure 4.17 Ventolin: World Sales Forecast ($bn), 2012-2017
Figure 4.18 Ventolin: World Sales Forecast ($bn), 2018-2023
Figure 4.19 ProAir: World Sales Forecast ($bn), 2012-2017
Figure 4.20 ProAir: World Sales Forecast ($bn), 2018-2023
Figure 4.21 Xopenex: World Sales Forecast ($bn), 2012-2017
Figure 4.22 Xopenex: World Sales Forecast ($bn), 2018-2023
Figure 4.23 Proventil: World Sales Forecast ($bn), 2012-2017
Figure 4.24 Proventil: World Sales Forecast ($bn), 2018-2023
Figure 4.25 The World Long-Acting Beta-2 Agonists (LABA) Mono-Therapy Market: Market Shares (%) by Leading Drugs, 2012
Figure 4.26 The World Long-Acting Beta-2 Agonists (LABA) Mono-Therapy Market: Revenues ($bn) by Leading Drugs, 2012
Figure 4.27 World Long-Acting Beta-2 Agonist Mono-Therapy Market: Market Shares (%) by Leading Drugs, 2017
Figure 4.28 World Long-Acting Beta 2 Agonist Mono-Therapy Market: Revenues ($bn) by Leading Drugs, 2017
Figure 4.29 World Long-Acting Beta2 Agonist Mono-Therapy Market: Market Shares (%) by Leading Drugs, 2023
Figure 4.30 World Long-Acting Beta2 Agonist Mono-Therapy Market: Revenues ($bn) by Leading Drugs, 2023
Figure 4.31 World Long-Acting Beta-2 Agonist Mono-Therapy Market: Sales Forecast ($bn) by Leading Drugs, 2012-2017
Figure 4.32 World Long-Acting Beta-2 Agonist Mono-Therapy Market: Sales Forecast ($bn) by Leading Drugs, 2018-2023
Figure 4.33 Serevent: World Sales Forecast ($bn), 2012-2017
Figure 4.34 Serevent: World Sales Forecast ($bn), 2018-2023
Figure 4.35 Foradil: World Sales Forecast ($bn), 2012-2017
Figure 4.36 Foradil Market: World Sales Forecast ($bn), 2018-2023
Figure 4.37 Onbrez Breezhaler: World Sales Forecast ($bn), 2012-2017
Figure 4.38 Onbrez Breezhaler: World Sales Forecast ($bn), 2018-2023
Figure 4.39 The World Anticholinergic Mono-Therapy Drug Market: Market Shares (%) by Leading Drugs, 2012
Figure 4.40 The World Anticholinergic Mono-Therapy Drug Market: Revenues ($bn) by Leading Drugs, 2012
Figure 4.41 The World Anticholinergic Market: Market Shares (%) by Leading Drugs, 2017
Figure 4.42 The World Anticholinergic Mono-Therapy Drug Market: Revenues ($bn) by Leading Drugs, 2017
Figure 4.43 The World Anticholinergic Market: Market Shares (%) by Leading Drugs, 2023
Figure 4.44 The World Anticholinergic Mono-Therapy Drug Market: Revenues ($bn) by Leading Drugs, 2023
Figure 4.45 The World Anticholinergic Mono-Therapy Drug Market: Sales Forecast ($bn) by Leading Drugs, 2012-2017
Figure 4.46 The World Anticholinergic Mono-Therapy Drug Market: Sales Forecast ($bn) by Leading Drugs, 2018-2023
Figure 4.47 Spiriva: World Sales Forecast ($bn), 2012-2017
Figure 4.48 Spiriva: World Sales Forecast ($bn), 2018-2023
Figure 4.49 Atrovent: World Sales Forecast ($bn), 2012-2017
Figure 4.50 Atrovent: World Sales Forecast ($bn) 2018-2023
Figure 5.1 The World Asthma and COPD Market: Anti-Inflammatory Drugs Market Shares (%) by Type, 2012
Figure 5.2 The World Asthma and COPD Market: Anti-Inflammatory Drugs Revenues ($bn) by Type, 2012
Figure 5.3 The World Asthma and COPD Market: Anti-Inflammatory Drugs Market Shares (%) by Type, 2017
Figure 5.4 The World Asthma and COPD Market: Anti-Inflammatory Drugs Revenues ($bn) by Type, 2017
Figure 5.5 The World Asthma and COPD Market: Anti-Inflammatory Drugs Market Share (%) by Type, 2023
Figure 5.6 The World Asthma and COPD Market: Anti-Inflammatory Drugs Revenues ($bn) by Type, 2023
Figure 5.7 The World Asthma and COPD Market: Anti-Inflammatory Drugs Sales Forecast ($bn) by Type, 2012-2017
Figure 5.8 The World Asthma and COPD Market: Anti-Inflammatory Drugs Sales Forecast ($bn) by Type, 2018-2023
Figure 5.9 The World Asthma and COPD Market: Corticosteroids Market Shares (%) by Leading Drugs, 2012
Figure 5.10 The World Asthma and COPD Market: Corticosteroids Revenues ($bn) by Leading Drugs, 2012
Figure 5.11 The World Asthma and COPD Market: Corticosteroids Market Shares (%) by Leading Drugs, 2017
Figure 5.12 The World Asthma and COPD Market: Corticosteroids Revenues ($bn) by Leading Drugs, 2017
Figure 5.13 The World Asthma and COPD Market: Corticosteroids Market Shares (%) by Leading Drugs, 2023
Figure 5.14 The World Asthma and COPD Market: Corticosteroid Revenues ($bn) by Leading Drugs, 2023
Figure 5.15 The World Asthma and COPD Market: Corticosteroids Sales Forecast ($bn) by Leading Drugs, 2012-2017
Figure 5.16 The World Asthma and COPD Market: Corticosteroids Sales Forecast ($bn) by Leading Drugs, 2018-2023
Figure 5.17 Flixotide: World Sales Forecast ($bn), 2012-2017
Figure 5.18 Flixotide: World Sales Forecast ($bn), 2018-2023
Figure 5.19 Pulmicort: World Sales Forecast ($bn), 2012-2017
Figure 5.20 Pulmicort: World Sales Forecast ($bn), 2018-2023
Figure 5.21 Qvar: World Sales Forecast ($bn), 2012-2017
Figure 5.22 Qvar: World Sales Forecast ($bn), 2018-2023
Figure 5.23 Asmanex: World Sales Forecast ($bn), 2012-2017
Figure 5.24 Asmanex: World Sales Forecast ($bn), 2018-2023
Figure 5.25 The World Anti-leukotrienes Market: Market Shares (%) by Leading Drugs, 2012
Figure 5.26 The World Anti-leukotrienes Market: Revenues ($bn) by Leading Drugs, 2012
Figure 5.27 The World Anti-Leukotrienes Market: Market Shares (%) by Leading Drugs, 2017
Figure 5.28 The World Anti-Leukotrienes Market: Revenues ($bn) by Leading Drugs, 2017
Figure 5.29 The World Anti-Leukotrienes Market: Market Shares (%) by Leading Drugs, 2023
Figure 5.30 The World Anti-Leukotrienes Market: Revenues ($bn) by Leading Drugs, 2023
Figure 5.31 The World Anti-Leukotrienes Market: Sales Forecast ($bn) by Leading Drugs, 2012-2017
Figure 5.32 The World Anti-Leukotrienes Market: Sales Forecast ($bn) by Leading Drugs, 2018-2023
Figure 5.33 Singulair: World Sales Forecast ($bn), 2012-2017
Figure 5.34 Singulair: World Sales Forecast ($bn), 2018-2023
Figure 5.35 The World Asthma and COPD Market: Monoclonal Antibodies Market Shares (%) by Drugs, 2017
Figure 5.36 The World Asthma and COPD Market: Monoclonal Antibodies Revenues ($bn) by Drugs, 2017
Figure 5.37 The World Asthma and COPD Market: Monoclonal Antibodies Market Shares (%) by Drugs, 2023
Figure 5.38 The World Asthma and COPD Market: Monoclonal Antibodies Revenues ($bn) by Drugs, 2023
Figure 5.39 The World Asthma and COPD Market: Monoclonal Antibodies Sales Forecast ($bn) by Drugs, 2012-2017
Figure 5.40 The World Asthma and COPD Market: Monoclonal Antibodies Sales Forecast ($bn) by Drugs, 2018-2023
Figure 5.41 Xolair: World Sales Forecast ($bn), 2012-2017
Figure 5.42 Xolair: World Sales Forecast ($bn), 2018-2023
Figure 6.1 The World Combination Drugs Market: Market Shares (%) by Leading Drugs, 2012
Figure 6.2 The World Combination Drugs Market: Revenues ($bn) by Leading Drugs, 2012
Figure 6.3 The World Combination Drugs Market: Market Shares (%) by Leading Drugs, 2017
Figure 6.4 The World Combination Drugs Market: Revenues ($bn) by Leading Drugs, 2017
Figure 6.5 The World Combination Drugs Market: Market Shares (%) by Leading Drugs, 2023
Figure 6.6 The World Combination Drugs Market: Revenues ($bn) by Leading Drugs, 2023
Figure 6.7 The World Combination Drug Market: Sales Forecast ($bn) by Leading Drugs, 2012-2017
Figure 6.8 The World Combination Drug Market: Sales Forecast ($bn) by Leading Drugs, 2018-2023
Figure 6.9 Seretide/Advair: World Sales Forecast ($bn), 2012-2017
Figure 6.10 Seretide/Advair: World Sales Forecast ($bn), 2018-2023
Figure 6.11 Symbicort: World Sales Forecast ($bn), 2012-2017
Figure 6.12 Symbicort: World Sales Forecast ($bn), 2018-2023
Figure 6.13 Combivent: World Sales Forecast ($bn), 2012-2017
Figure 6.14 Combivent: World Sales Forecast ($bn), 2018-2023
Figure 6.15 Dulera: World Sales Forecast ($bn), 2012-2017
Figure 6.16 Dulera: World Sales Forecast ($bn), 2018-2023
Figure 7.1 The Global Asthma and COPD Market: Market Shares (%) by Region, 2012
Figure 7.2 The Global Asthma and COPD Market: Revenues ($bn) by Region, 2012
Figure 7.3 The Global Asthma & COPD Market: Market Shares (%) by Region, 2017
Figure 7.4 The Global Asthma & COPD Market: Revenues ($bn) by Region, 2017
Figure 7.5 The Global Asthma & COPD Market: Market Share (%) by Region, 2023
Figure 7.6 The Global Asthma & COPD Market: Revenues ($bn) by Region, 2023
Figure 7.7 Global Asthma and COPD Market: Revenue Forecast ($bn) by Region, 2012-2017
Figure 7.8 Global Asthma and COPD Market: Revenues Forecast ($bn) by Region, 2018-2023
Figure 7.9 The US Asthma and COPD Market: Sales Forecast ($bn, AGR%, CAGR%), 2012-2023
Figure 7.10 The Japanese Asthma and COPD Market: Sales Forecast ($bn, AGR%, CAGR%), 2012-2023
Figure 7.11 The EU5 Asthma and COPD Markets: Market Shares (%) by Country, 2012
Figure 7.12 The EU5 Asthma and COPD Markets: Revenues ($bn) by Country, 2012
Figure 7.13 The EU5 Asthma and COPD Markets: Market Shares (%) by Country, 2017
Figure 7.14 The EU5 Asthma and COPD Markets: Revenues ($bn) by Country, 2017
Figure 7.15 The EU5 Asthma and COPD Markets: Market Shares (%) by Country, 2023
Figure 7.16 The EU5 Asthma and COPD Markets: Revenues ($bn) by Country, 2023
Figure 7.17 The EU5 Asthma and COPD Markets: Revenue Forecast ($bn) by Country, 2012-2017
Figure 7.18 The EU5 Asthma and COPD Markets: Revenue Forecast ($bn), 2012-2017
Figure 7.19 The EU5 Asthma and COPD Markets: Revenue Forecast ($bn) by Country, 2018-2023
Figure 7.20 The EU5 Asthma and COPD Markets: Revenue Forecast ($bn), 2018-2023
Figure 7.21 The BRIC Nations: Market Shares (%) by Country, 2012
Figure 7.22 The BRIC Nations: Revenues ($bn) by Country, 2012
Figure 7.23 The BRIC Nations: Market Shares (%) by Country, 2017
Figure 7.24 The BRIC Nations: Revenues ($bn) by Country, 2017
Figure 7.25 The BRIC Nations: Market Shares (%) by Country, 2023
Figure 7.26 The BRIC Nations: Revenues ($bn) by Country, 2023
Figure 7.27 The BRIC Nations: Sales Forecast ($bn) by Country, 2012-2017
Figure 7.28 The BRIC Nations: Sales Forecast ($bn, AGR%, CAGR%), 2013-2017
Figure 7.29 The BRIC Nations: Sales Forecast ($bn) by Country 2018-2023
Figure 7.30 BRIC Nations: Sales Forecast ($bn), 2018-2023
Figure 8.1 The Global Asthma and COPD Market: Market Shares (%) by Leading Companies, 2012
Figure 8.2 The Global Asthma and COPD Market: Revenues ($bn) by Leading Companies, 2012
Figure 8.3 Global Asthma and COPD Market: Market Shares (%) by Leading Companies, 2017
Figure 8.4 Global Asthma and COPD Market: Revenues ($bn) by Leading Companies, 2017
Figure 8.5 Global Asthma and COPD Market: Market Shares (%) by Leading Companies, 2023
Figure 8.6 Global Asthma and COPD Market: Revenues ($bn) by Leading Companies, 2023
Figure 8.7 Global Asthma and COPD Market: Revenue Forecast ($bn) by Leading Companies, 2012-2017
Figure 8.8 Global Asthma and COPD Market: Revenue Forecast ($bn) by Leading Companies, 2018-2023
Figure 8.9 GSK: Revenue Shares (%) by Leading Products, 2012
Figure 8.10 GSK: Revenues ($bn) by Leading Products, 2012
Figure 8.11 GSK: Asthma and COPD Revenue Forecast ($bn) by Drugs, 2012-2017
Figure 8.12 GSK: Asthma and COPD Revenue Forecast ($bn), 2012-2017
Figure 8.13 GSK: Asthma and COPD Revenue Forecast ($bn) by Drugs, 2018-2023
Figure 8.14 GSK: Asthma and COPD Revenue Forecast ($bn), 2018-2023
Figure 8.15 Boehringer: Asthma and COPD Revenue Shares (%) by Leading Products, 2012
Figure 8.16 Boehringer: Asthma and COPD Revenues ($bn) by Leading Products, 2012
Figure 8.17 Boehringer: Asthma and COPD Revenue Forecast ($bn) by Drugs, 2012-2017
Figure 8.18 Boehringer: Asthma and COPD Revenue Forecast ($bn), 2012-2017
Figure 8.19 Boehringer: Asthma and COPD Revenue Forecast ($bn) by Drugs, 2018-2023
Figure 8.20 Boehringer: Asthma and COPD Revenue Forecast ($bn), 2018-2023
Figure 8.21 Merck: Asthma and COPD Revenue Shares (%) by Leading Products, 2012
Figure 8.22 Merck: Asthma and COPD Revenues ($bn) by Leading Products, 2012
Figure 8.23 Merck: Asthma and COPD Revenue Forecast ($bn) by Drugs, 2012-2017
Figure 8.24 Merck: Asthma and COPD Revenue Forecast ($bn), 2012-2017
Figure 8.25 Merck: Asthma and COPD Revenue Forecast ($bn) by Drugs, 2018-2023
Figure 8.26 Merck: Asthma and COPD Revenue Forecast ($bn), 2018-2023
Figure 8.27 AstraZeneca: Asthma and COPD Revenue Shares (%) by Leading Products, 2012
Figure 8.28 AstraZeneca: Asthma and COPD Revenues ($bn) by Leading Products, 2012
Figure 8.29 AstraZeneca: Asthma Revenue Forecast ($bn) by Drugs, 2012-2017
Figure 8.30 AstraZeneca: Asthma and COPD Revenue Forecast ($bn), 2012-2017
Figure 8.31 AstraZeneca: Asthma and COPD Therapies Revenue Forecast ($bn) by Drugs, 2018-2023
Figure 8.32 AstraZeneca: Asthma and COPD Revenue Forecast ($bn), 2018-2023
Figure 8.33 Novartis: Asthma and COPD Revenue Shares (%) by Leading Products, 2012
Figure 8.34 Novartis: Asthma and COPD Revenues ($bn) by Leading Products, 2012
Figure 8.35 Novartis: Asthma and COPD Revenue Forecast ($bn) by Drugs, 2012-2017
Figure 8.36 Novartis: Asthma and COPD Revenue Forecast ($bn), 2012-2017
Figure 8.37 Novartis: Asthma and COPD Revenue Forecast ($bn) by Drugs, 2018-2023
Figure 8.38 Novartis: Asthma and COPD Revenue Forecast ($bn), 2018-2023
Figure 8.39 Teva: Asthma and COPD Revenue Shares (%) by Leading Products, 2012
Figure 8.40 Teva: Asthma and COPD Revenues ($bn) by Leading Products, 2012
Figure 8.41 Teva: Asthma and COPD Revenue Forecast ($bn) by Drugs, 2012-2017
Figure 8.42 Teva: Asthma and COPD Revenue Forecast ($bn), 2012-2017
Figure 8.43 Teva: Asthma and COPD Revenue Forecast ($bn) by Drugs, 2018-2023
Figure 8.44 Teva: Asthma and COPD Segment: Revenue Forecast ($bn), 2018-2023
Figure 12.1 The World Asthma and COPD Market: Sales Forecast ($bn) by Therapy Area, 2013-2023
To view free sample pages of this report please click here
3M
Almirall
American Thoracic Society (ATS)
AstraZeneca
Aurobindo Pharma
Boehringer Ingelheim
British Lung Foundation (BLF)
Canadian Lung Foundation
Canadian Thoracic Society
Centers of Disease Control and Prevention (CDC)
Cheisi Farmeceutici
Cipla
Dainippon Sumitomo Pharma
Dr Reddy Laboratories
Education For Health
European Federation of Allergy and Airway Diseases
European Lung Foundation (ELF)
European Medicines Agency (EMA)
European Respiratory Journal
European Respiratory Society (ERS)
Food and Drug Administration (FDA)
Genentech (Subsidiary of Roche)
GeoPharm
GlaxoSmithKline
Global Initiative for Asthma (GINA)
Global Initiative for Obstructive Lung Disease (GOLD)
Merck
Mylan Inc
National Heart, Lung, and Blood Institute
National Institute for Health and Care Excellence (NICE)
National Institutes of Health
Natural Medicine Magazine
Novartis
Olmsted Medical Center
Ono Pharmaceuticals
Orchid Chemicals and Pharmaceuticals
Pearl Therapeutics (Acquired by Astrazeneca)
Perrigo
Pharmaceutical Research and Manufacturers of America (PhRMA)
Ranbaxy
Roche
Sandoz (Subsidiary of Novartis)
Schering Plough (Acquired by Merck)
Sunovion Pharmaceuticals
Tanox Inc
Teva
Theravance Pharmaceuticals
University of Minnesota
Vectura Pharmaceuticals
World Health Organization (WHO)
To view free sample pages of this report please click here
Download sample pages
Complete the form below to download your free sample pages for Asthma and COPD Therapies: World Market 2013-2023Download sample pages
Complete the form below to download your free sample pages for Asthma and COPD Therapies: World Market 2013-2023Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
What are the dynamic growth sectors? where are the regional business opportunities?
Which technologies will prevail and who are the leading companies succeeding in these sectors and why?
If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.
If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Visiongain Publishes Direct-to-Patient Market Report 2021-2031
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Visiongain Publishes Pharma Contract Sales Market Report 2021-2031
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
